Esnault C - Search Results

1

Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia.

McKenzie MD, Ghisi M, Oxley EP, Ngo S, Cimmino L, Esnault C, Liu R, Salmon JM, Bell CC, Ahmed N, Erlichster M, Witkowski MT, Liu GJ, Chopin M, Dakic A, Simankowicz E, Pomilio G, Vu T, Krsmanovic P, Su S, Tian L, Baldwin TM, Zalcenstein DA, DiRago L, Wang S, Metcalf D, Johnstone RW, Croker BA, Lancaster GI, Murphy AJ, Naik SH, Nutt SL, Pospisil V, Schroeder T, Wall M, Dawson MA, Wei AH, de Thé H, Ritchie ME, Zuber J, Dickins RA. McKenzie MD, et al. Among authors: esnault c. Cell Stem Cell. 2019 Aug 1;25(2):258-272.e9. doi: 10.1016/j.stem.2019.07.001. Cell Stem Cell. 2019. PMID: 31374198 Free article.

2

Retinoids in hematology: a timely revival?

Geoffroy MC, Esnault C, de Thé H. Geoffroy MC, et al. Among authors: esnault c. Blood. 2021 May 6;137(18):2429-2437. doi: 10.1182/blood.2020010100. Blood. 2021. PMID: 33651885 Free article. Review.

3

[Arsenic: The gold standard for acute promyelocytic leukaemia with FLT3-ITD mutation].

Esnault C, Rahmé R, de Thé H. Esnault C, et al. Med Sci (Paris). 2021 May;37(5):544-546. doi: 10.1051/medsci/2021048. Epub 2021 May 18. Med Sci (Paris). 2021. PMID: 34003103 Free article. French. No abstract available.

4

p53 as an Effector or Inhibitor of Therapy Response.

Ablain J, Poirot B, Esnault C, Lehmann-Che J, de Thé H. Ablain J, et al. Among authors: esnault c. Cold Spring Harb Perspect Med. 2015 Dec 4;6(1):a026260. doi: 10.1101/cshperspect.a026260. Cold Spring Harb Perspect Med. 2015. PMID: 26637438 Free PMC article. Review.

5

FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias.

Esnault C, Rahmé R, Rice KL, Berthier C, Gaillard C, Quentin S, Maubert AL, Kogan S, de Thé H. Esnault C, et al. Blood. 2019 Mar 28;133(13):1495-1506. doi: 10.1182/blood-2018-07-866095. Epub 2019 Jan 23. Blood. 2019. PMID: 30674471 Free PMC article.

6

SV40 induced cellular immortalization: phenotypic changes associated with the loss of proliferative capacity in a conditionally immortalized cell line.

Mignotte B, Larcher JC, Zheng DQ, Esnault C, Coulaud D, Feunteun J. Mignotte B, et al. Among authors: esnault c. Oncogene. 1990 Oct;5(10):1529-33. Oncogene. 1990. PMID: 2174526

7

Selective alteration of mitochondrial function by Ditercalinium (NSC 335153), a DNA bisintercalating agent.

Esnault C, Brown SC, Segal-Bendirdjian E, Coulaud D, Mishal Z, Roques BP, Le Pecq JB. Esnault C, et al. Biochem Pharmacol. 1990 Jan 1;39(1):109-22. doi: 10.1016/0006-2952(90)90654-4. Biochem Pharmacol. 1990. PMID: 2297352

8

Recognition by the DNA repair system of DNA structural alterations induced by reversible drug-DNA interactions.

Lambert B, Segal-Bendirdjian E, Esnault C, Le Pecq JB, Roques BP, Jones B, Yeung AT. Lambert B, et al. Among authors: esnault c. Anticancer Drug Des. 1990 Feb;5(1):43-53. Anticancer Drug Des. 1990. PMID: 2180423

9

Effects of the bifunctional antitumor intercalator ditercalinium on DNA in mouse leukemia L1210 cells and DNA topoisomerase II.

Markovits J, Pommier Y, Mattern MR, Esnault C, Roques BP, Le Pecq JB, Kohn KW. Markovits J, et al. Among authors: esnault c. Cancer Res. 1986 Nov;46(11):5821-6. Cancer Res. 1986. PMID: 3019538

10

Rational design of bis-intercalating drugs as antitumour agents: importance of rigidity in the linking chain.

Garbay-Jaureguiberry C, Esnault C, Delepierre M, Laugaa P, Laalami S, Le Pecq JB, Roques BP. Garbay-Jaureguiberry C, et al. Among authors: esnault c. Drugs Exp Clin Res. 1987;13(6):353-7. Drugs Exp Clin Res. 1987. PMID: 3652924

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

108 results

Search Page

Filters